Precision Biosciences Inc
DTIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357874
No open-market purchases or sales by Precision Biosciences Inc insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $138.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Precision Biosciences Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Precision Biosciences Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Germano Geno J | Director | 44,883 | Jun 5, 2026 | 3 |
| Brown Melinda | Director | 44,346 | Jun 5, 2026 | 3 |
| Buehler Kevin | Director | 49,137 | Jun 5, 2026 | 2 |
| Frankel Stanley | Director | 40,478 | Jun 5, 2026 | 4 |
| Pire Shari Lisa | Director | 35,028 | Jun 5, 2026 | 2 |
| Kelly John Alexander | Chief Financial Officer | 125,883 | Jun 3, 2026 | 4 |
| Smith J. Jefferson | Chief Research Officer | 121,926 | Jun 3, 2026 | 3 |
| Scimeca Dario | General Counsel and Secretary | 56,457 | Jun 3, 2026 | 4 |
| Amoroso Michael | President and CEO | 243,392 | Jun 3, 2026 | 4 |
| Wadsworth Samuel C. | Director | 4,202 | Jun 6, 2024 | 0 |
| List Alan | Chief Medical Officer | 4,488 | May 3, 2024 | 0 |
| Barton Shane | VP & Corporate Controller | 27,502 | Jun 9, 2023 | 0 |
| Jantz Derek | Chief Scientific Officer | 4,055,174 | Jun 9, 2022 | 0 |
| Schinazi Raymond F | Director | – | May 12, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2023 (view filing) | Jun 8 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −13.4K | $0.75 | −$10.0K | −16.3%68.5K after | 10b5-1 |
| Apr 28, 2023 (view filing) | Apr 27 | 1 day | List AlanChief Medical Officer | SSale | −7.77K | $0.79 | −$6.14K | −12.1%56.5K after | 10b5-1 |
| Mar 23, 2023 (view filing) | Mar 22 | 1 day | Amoroso MichaelPresident and CEO | SSale | −47.0K | $0.82 | −$38.5K | −40.6%68.7K after | 10b5-1 |
| Mar 21, 2023 (view filing) | Mar 17 | 4 days | Kelly John AlexanderChief Financial Officer | PPurchase | +20.0K | $0.86 | +$17.2K | +8.9%245.6K after | |
| Mar 7, 2023 (view filing) | Mar 6 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −12.2K | $1.07 | −$13.0K | −19.6%50.1K after | |
| Mar 7, 2023 (view filing) | Mar 6 | 1 day | List AlanChief Medical Officer | SSale | −9.47K | $1.07 | −$10.1K | −19.9%38.2K after | |
| Oct 18, 2022 (view filing) | Oct 17 | 1 day | Amoroso MichaelPresident and CEO | SSale | −11.0K | $1.32 | −$14.5K | −45.5%13.2K after | |
| Sep 26, 2022 (view filing) | Sep 22-23 | 4 days | Kelly John AlexanderChief Financial Officer | PPurchase | +45.2K | $1.32 | +$59.7K | +38.4%162.9K after | 2 lots |
| Jun 24, 2022 (view filing) | Jun 22 | 2 days | Kelly John AlexanderChief Financial Officer | PPurchase | +33.8K | $1.50 | +$50.7K | +40.3%117.7K after | |
| Jun 9, 2022 (view filing) | Jun 8 | 1 day | Jantz DerekChief Scientific Officer | SSale | −18.8K | $2.06 | −$38.8K | −0.5%4.06M after | |
| Jun 9, 2022 (view filing) | Jun 8 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −9.83K | $2.06 | −$20.3K | −23.2%32.5K after | |
| Apr 28, 2022 (view filing) | Apr 27 | 1 day | List AlanChief Medical Officer | SSale | −7.78K | $2.10 | −$16.3K | −29.9%18.3K after | |
| Mar 21, 2022 (view filing) | Mar 17 | 4 days | Kelly John AlexanderChief Financial Officer | PPurchase | +16.7K | $3.08 | +$51.4K | +85.5%36.2K after |